Human papillomavirus type 16 E6 oncoprotein-derived epitopes (HPV-16 E6 epitopes) (HPV-16 E6 epitopes)

Human papillomavirus type 16 (HPV-16) E6 oncoprotein-derived epitopes are specific peptide fragments of the E6 protein, which is a primary driver of oncogenesis in high-risk HPV infections (UniProt: P03126) [1]. The E6 protein functions by binding to the host cell's E6-associated protein (E6AP) and the tumor suppressor p53, leading to the ubiquitin-mediated degradation of p53 and the subsequent inhibition of apoptosis (PubMed: 15936061) [5]. These epitopes are critical targets for therapeutic interventions, particularly vaccines and adoptive T-cell therapies, aimed at treating HPV-16-associated malignancies such as cervical and head and neck cancers (PubMed: 20018967) [2]. By presenting these viral peptides on the surface of infected or malignant cells via Major Histocompatibility Complex (MHC) molecules, they provide a mechanism for the immune system to distinguish cancerous cells from healthy ones. Therapeutic strategies like ISA101 and VGX-3100 utilize these epitopes to stimulate a robust CD8+ cytotoxic T-cell response to eradicate tumor cells (PubMed: 26386534) [3]. However, the efficacy of these treatments can be limited by the diversity of human leukocyte antigen (HLA) types and the immunosuppressive environment within the tumor (StatPearls: HPV) [4]. Clinical monitoring often involves measuring T-cell responses against these specific epitopes to gauge vaccine efficacy.

Other names

HPV16 E6 peptidesHPV-16 E6 antigensHuman papillomavirus 16 E6 protein fragmentsE6-derived T-cell epitopes

Induction of antigen-specific T-cell mediated immune response against HPV-16 infected cells